Metformin's case as an anti-ageing drug now rests on three null results
Twenty-one years of cancer follow-up, multimorbidity data to 2021, and a randomised trial in frail older adults. In each, metformin did not beat placebo. Lifestyle change did.
Loneliness is not literally 'as deadly as 15 cigarettes.' The evidence is still striking.
The famous cigarette comparison is a communications gloss on a robust but observational finding: people with stronger social ties are markedly more likely to survive follow-up.
A philanthropist is paying for the rapamycin trial no drug company would fund
A $12 million gift will test whether low-dose rapamycin changes the transition to frailty in adults over 65 — the first study of the drug designed around an outcome rather than a biomarker.
PEARL rapamycin trial results: safe over a year, primary endpoint unmoved
The longest human trial of low-dose rapamycin for healthy ageing found no change in visceral fat, its own primary outcome. The positive findings it is quoted for rest on eight women.
Golf's split evidence: good for population health, hard on elite bodies
The same sport that a 300,000-person Swedish cohort associated with a 40% lower death rate carries an injury incidence in professionals roughly six times that of amateurs. The difference is dose.
NAD+ drips are a $250-to-1,500 wellness habit with no completed outcome trials
A systematic review of 113 studies found real biology in NAD+ supplementation — and not one eligible human trial testing the IV or IM version clinics actually sell for anti-aging.
Dubai just created a government agency whose only job is regulating longevity medicine
The Dubai Longevity Authority will oversee everything from lab research to the clinics selling anti-aging treatments — a regulatory structure that doesn't really exist yet anywhere else.
The first human test of epigenetic reprogramming is an eye trial in 18 people
Three of the four Yamanaka factors, delivered to one eye and switched on with an antibiotic for eight weeks. The mouse data are striking; the trial is a safety study and will not measure ageing.
Fewer than a dozen trials: the whole human evidence base for longevity rapamycin
A 2025 review walked through every study of low-dose rapamycin in healthy adults. The immune findings are real, the outcome data do not exist, and the review's own worked example does not add up.
Senolytics: two randomised trials, and no confirmed clinical benefit yet
A phase 2 trial of dasatinib plus quercetin missed its bone endpoint. A senolytic injected into the eye produced a 5.6-letter vision gain whose confidence interval crosses zero.
Compounded rapamycin delivers less drug per milligram than the commercial pill
Two real-world cohorts found lower blood levels per milligram from compounded formulations — and the longest longevity trial of rapamycin was run on the weaker one, which changes how to read it.
Taurine does not fall with age after all, a second Science paper reports
In 2023 declining taurine was proposed as a driver of ageing. Two years later the same journal published human, monkey and mouse data in which taurine rose or stayed flat.
Lifting has replaced weight loss at the top of the New Year list
A December survey found getting stronger is the leading 2026 health goal. The best meta-analysis of muscle-strengthening and mortality finds a benefit that plateaus at around 30 to 60 minutes a week.